Login to Your Account


Capstone Crushed on Phase IIa Data; Firm Optimistic

By Jennifer Boggs


Wednesday, December 15, 2010
Shares of Capstone Therapeutics were walloped after data from Phase IIa pilot trials testing antifibrotic peptide AZX100 in keloid scarring fell short of showing statistical significance, but company executives maintained that the drug warrants further development.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription


»

BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Privacy Policy | Terms of Use
 
Part of Thompson Media Group LLC

Free Ezine

Sign up for Perspectives FREE e-mail newsletter.

Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.